Merck believes ‘molnupiravir’ is effective against ‘Omicron’.
Date 01 Dec 2021 time 12:06
Merck points out anti-COVID pills ‘Molnupiravir’ also tends to resist omicrons.
Bloomberg reported Nov. 30, Merck & Co. said in a statement it expected the anti-COVID-19 pill. mole nupiravir The company’s molnupiravir will work against COVID-19. Omicron species according to the mechanism of action of the drug and the current genetic information
Merck, however, is not conducting specific research to determine the effectiveness of molnupiravir against COVID-19. Omicron species But previously it was found that the drug could be used for COVID-19. Delta, Gamma and Miu species
A recent study found that molnupiravir could reduce the risk of hospitalization or death among COVID-19 patients by 30% after it was previously said to reduce the risk. 50%
Merck filed for molnupiravir with the U.S. Food and Drug Administration (FDA) in October, when the FDA’s advisory committee voted 13 to 10 to approve it. The use of such drugs and will be submitted to the FDA for approval next.
Molnupiravir has also been approved by the UK Drug and Healthcare Regulatory Agency (MHRA), the first country in the world to approve the drug.
Photo by Handout / Merck & Co,Inc. / AFP